

CLINICAL SCIENCE

Guidance for Authors 1992

CONTENTS

	<i>page</i>
I. Policy of the Journal	
1.1. Scope	i
1.2. The Editorial Board	i
1.3. The editorial process.	i
1.4. Ethics of investigations	i
1.5. Originality of papers	ii
2. Submission of Manuscripts: General Information and Format	
2.1. General	ii
2.2. Full papers.	ii
2.3. Rapid communications	iii
2.4. Correspondence	iii
2.5. Editorial reviews	iii
2.6. Arrangements for large amounts of information	iii
2.7. Proof corrections	iii
2.8. Offprints	iii
2.9. Availability on MEDLINE	iii
3. Miscellaneous Notes	
3.1. Abbreviations	iii
3.2. Anatomical nomenclature.	iii
3.3. Animals, plants and micro-organisms	iv
3.4. Buffers and salts	iv
3.5. Computer modelling	iv
3.6. Doses.	iv
3.7. Enzymes	iv
3.8. Evaluation of measurement procedures.	iv
3.9. Figures and Tables	iv
3.10. Footnotes	v
3.11. 'Homology'	v
3.12. Isotope measurements	v
3.13. Radionuclide applications in man	v
3.14. Methods	v
3.15. Nomenclature of disease	v
3.16. Powers in Tables and Figures	v
3.17. References.	v
3.18. Solutions	v
3.19. Spectrophotometric data	vi
3.20. Spelling	vi
3.21. Statistics	vi
3.22. Trade names	vi
4. Units: The SI System	vi
5. Abbreviations, Conventions etc.	vii

I. POLICY OF THE JOURNAL

I.1. Scope

Clinical Science publishes papers in the field of clinical investigation, provided they are of a suitable standard and contribute to the advancement of knowledge in this field. The term 'clinical investigation' is used in its broadest sense to include studies in animals and the whole range of biochemical, physiological, immunological and other approaches that may have relevance to disease in man. Studies which are confined to normal subjects, or animals, or are purely methodological in nature may be acceptable. The material presented should permit conclusions to be drawn and should not be only of a preliminary nature. The journal publishes four types of manuscript, namely invited Editorial Reviews, Full Papers, Rapid Communications and Correspondence. In addition, *Clinical Science* publishes abstracts of the proceedings of the Medical Research Society (as Supplements) and also the Society's Annual Guest Lecture.

I.2. The Editorial Board

The Board comprises Editors for the Medical Research Society and the Biochemical Society and a Chairman and two Deputy Chairmen who are drawn alternately from the two Societies. Members of the Board retire after a maximum of 5 years; the Chairman serves in his capacity for 2 years. The membership of the Board is designed to cover as wide a range of interests as possible.

The main function of the Board is to decide on the acceptability of submitted papers, but it also deals with general matters of editorial policy. Financial policy is dealt with separately by the Committee of Management.

I.3. The editorial process

A submitted paper is first read by the Chairman or one of the Deputy Chairmen of the Editorial Board who then sends it to an Editor. The latter considers the paper in detail and sends it to one or more referees (who remain anonymous) from outside the membership of the Board. The Editor returns it with his recommendation to the Chairman who then writes formally to the authors. The ultimate responsibility of acceptance for publication lies with the Chairman. If the Chairman is for any reason unavailable, a Deputy Chairman assumes this function.

I.4. Ethics of investigations

(a) Human subjects. Authors must state in the text of their paper the manner in which they have complied,

where necessary, with the recommendations on human investigations published in the Medical Research Council report of 1962/63 *Br. Med. J.* 1964; **ii**, 178–80. Consent **must** be obtained from each patient or subject after full explanation of the purpose, nature and risks of all procedures used, and the fact that such consent has been given should be recorded in the paper. Papers should also state that the Ethical Committee of the Institution in which the work was performed has given approval to the protocol.

(b) **Animals.** Care must always be taken to ensure that experimental animals do not suffer unnecessarily. Authors must state in the text the anaesthetic procedures used in full, and all precautions they took to ensure that the animals did not suffer unduly during and after the experimental procedure.

The Editorial Board will not accept papers where the ethical aspects are, in the Board's opinion, open to doubt.

1.5. Originality of papers

- ▶ Submission of a paper to *Clinical Science* implies that it has been approved by all the named authors, that all persons entitled to authorship have been so named, that it reports unpublished work that is not under consideration for publication elsewhere, and that if the paper is accepted for publication the authors will transfer to the Biochemical Society the copyright of the paper, which will then not be published elsewhere in the same form, in any language, without the consent of the Society. Authors will be required to sign an undertaking to these effects. The restriction on previous publication does not usually apply to previous publication of oral communications in brief abstract form. In such cases authors should enclose three copies of the abstracts or previous publications. Requests for consent for reproduction of material published in *Clinical Science* should be addressed to the Managing Editor.

2. SUBMISSION OF MANUSCRIPTS: GENERAL INFORMATION AND FORMAT

2.1. General

Papers submitted for publication should be sent to the Managing Editor, *Clinical Science*, 59 Portland Place, London W1N 3AJ, U.K. (telephone 071-637 5873; facsimile 071-323 1136). Authors in North America may send their papers to *Clinical Science*, Portland Press Inc., P.O. Box 2191, Chapel Hill, NC 27515-2191. The covering letter should include the author's telephone number and facsimile number (if available). Non-European authors will be sent the decision and the reports on their paper by facsimile.

The submission should contain four copies (of which three may be photocopies, except for half-tone figures) of the typescript, Tables, Figures etc. The authors should retain one copy of the paper. Typescripts produced on dot-matrix printers that are not of 'near letter quality' may be unacceptable. The Editorial Board does not accept

responsibility for damage or loss of papers submitted, although great care is taken to ensure safety and confidentiality of the typescript during the editorial process.

Papers should be presented so that they are intelligible to the non-specialist reader of the journal. This is particularly important in highly specialized fields and a very brief résumé of the current state of knowledge is usually helpful. Certain types of material, e.g. mathematical formulations requiring more than trivial derivations, should be given in a separate Appendix.

Where the reader is referred to previous works by the same author(s) for important details relevant to the present work, three copies or reprints of the publication should be sent with the typescript. This is of particular importance in relation to methodology.

The dates of receipt and acceptance of the paper will be published. If the paper has to be returned to the authors for revision and is not resubmitted within 3 months, the date of receipt will be revised accordingly and the revised paper may be treated as a new submission. It is emphasized that badly presented or unduly long papers will be returned for revision and delays in publication will be inevitable. Similar delays will be incurred if the typescript is not prepared strictly in accordance with the instructions detailed below.

Typescripts of rejected work will not be returned to authors unless a specific request for the return has been made at the time of submission.

2.2. Full papers

These may be of any length that is justified by their content. Authors should, however, note that because of pressure for space in the journal no paper, whatever its scientific merits, will be accepted if it exceeds the minimum length required for precision in describing the experiments and clarity in interpreting them. As a guide, most papers published in the journal are of between six and eight printed pages. A concise well-written paper tends to be published more rapidly. Extensive Tables of data can be deposited with the Royal Society of Medicine (see 2.6). *Guidance for Authors* is usually published in the January issue of the journal, and revised periodically.

The authors should refer to a current issue of *Clinical Science* to make themselves familiar with the general layout. Typescripts should be, in general, arranged as follows:

(a) *Title page.* Title: this should be as informative as possible, since titles of papers are being increasingly used in indexing and coding for information storage and retrieval. The title should indicate the species in which the observations reported have been made. The numbering of parts in a series of papers is not permitted.

List of authors' names (degrees and appointments are not required).

Laboratory or Institute of origin.

Key words: for indexing the subject of the paper; they should, if possible, be selected from the current issues of 'Medical Subject Headings' (MeSH), produced by the *Index Medicus*.

Short title: for use as a running heading in the printed text; it should not exceed forty-five characters and spaces and should not contain any abbreviations.

Author for correspondence: the name and address of the author to whom queries and requests for reprints should be sent.

(b) *Summary*. This should be a brief statement arranged in **numbered paragraphs** of what was done, what was found and what was concluded, and should rarely exceed 250 words. Abbreviations should be avoided as far as possible and must be defined. Statistical and methodological details including exact doses should also be avoided unless they are essential to the understanding of the Summary.

(c) *Introduction*. This should be comprehensible to the general reader and should contain a clear statement of the reason for doing the work, but should not include either the findings or the conclusions.

(d) *Methods*. The aim should be to give sufficient information in the text or by reference to permit the work to be repeated without the need to communicate with the author.

(e) *Results*. This section should not include material appropriate to the Discussion section.

(f) *Discussion*. This should not contain results and should be pertinent to the data presented.

(g) *Acknowledgments*. These should be as brief as possible.

(h) *References*. See p. v for the correct format.

(i) *Figures and Tables*. See p. iv.

2.3. Rapid communications

The passage of these papers through the editorial process will be expedited and contributors are encouraged to take advantage of this facility when rapid publication is of importance and when material can be presented concisely. Rapid Communications should describe completed work and should not be merely a preliminary communication.

To achieve rapid publication only a decision will be given, not an editorial report. In addition, authors of accepted Rapid Communications will not be sent proofs. Rejection of a paper submitted as a Rapid Communication does not preclude its re-submission as a full paper for publication in *Clinical Science*, in which event the paper would be reviewed and reports provided with the editorial decision in the normal way.

Rapid Communications should be similar in format to full papers, except that they must occupy not more than four printed pages. This is about 3000 words, with appropriate deductions (at the rate of 1000 words/page) for Figures and Tables.

2.4. Correspondence

Letters containing original observations or critical assessments of material published in *Clinical Science*, including Editorial Reviews, will be considered for the Correspondence section of the journal. Letters should be no longer than 750 words, with one Figure or Table and up to six references, or 1000 words maximum without a

Figure or Table. Letters relating to material previously published in *Clinical Science* should be submitted within 6 months of the appearance of the article concerned. They will be sent to the authors for comment and both the letter and any reply by the author will be published together. Further correspondence arising therefrom will also be considered for publication. Consideration will also be given to publication of letters on ethical matters.

2.5. Editorial reviews

These are normally commissioned. However, unsolicited reviews will be considered. Prospective authors should first submit a synopsis of their proposed review rather than the full typescript.

2.6. Arrangements for large amounts of information

It is impracticable to publish very large sets of individual values or very large numbers of diagrams, and under these circumstances a summary of the information only should be included in the paper. The information from which the summary was derived should be submitted with the typescript and, if the latter is accepted, the Editors may ask for a copy of the full information and diagrams to be deposited with the Librarian, the Royal Society of Medicine, 1 Wimpole Street, London W1M 8AE, who will issue copies on request. Experience has shown that such requests are frequently received.

2.7. Proof corrections

These are expensive and corrections of other than printers' errors may have to be charged to the author.

2.8. Offprints

Twenty-five offprints are supplied free and additional copies may be obtained at terms, based upon the cost of production, that will be given with the proofs. All offprints should be ordered when the proofs are returned (except for Rapid Communications, where they should be ordered when the subedited typescript is returned).

2.9. Availability on MEDLINE

Summaries of papers in *Clinical Science* are available on the MEDLINE system run by the National Library of Medicine, National Institutes of Health, Bethesda, Maryland, U.S.A.

3. MISCELLANEOUS NOTES

3.1. Abbreviations

Abbreviations should be avoided; if used they must be defined at the first mention; new abbreviations should be coined only for unwieldy names which occur frequently. Abbreviations should not appear in the title and short title nor, if possible, in the Summary. A list of accepted abbreviations is on p. vii. Numbers, not initials, should be used for patients and subjects.

3.2. Anatomical nomenclature

This should follow the recommendations of the International Anatomical Nomenclature Committee (Nomina

Anatomica. 3rd ed. Amsterdam: Excerpta Medica Foundation, 1966).

3.3. Animals, plants and micro-organisms

The full binomial specific names should be given at first mention for all experimental animals other than common laboratory animals. The strain and, if possible, the source of laboratory animals should be stated. Thereafter in the text, single letter abbreviations may be given for the genus; if two genera with the same initial letter are studied, abbreviations such as *Staph.* and *Strep.* should be used.

3.4. Buffers and salts

The acidic and basic components should be given, together with the pH. Alternatively, a reference to the composition of the buffer should be given. Further details are provided in *Biochem. J.* 1992; **281**, 1–19.

When describing solutions containing organic anions and their parent acids, the salt designator (e.g. lactate, urate, oxalate) should be used in preference to the name of the acid (lactic, uric, oxalic) unless it is certain that virtually all of the acid is in the undissociated form.

The composition of incubation media should be described, or a reference to the composition should be given.

3.5. Computer modelling

Papers concerned primarily with computer modelling techniques are acceptable provided that use of such techniques leads to a clear choice between two or more alternative hypotheses, or to the formulation of a new hypothesis amenable to experimental challenge or verification, or provides some new insight into the behaviour of a particular physiological system. Extensive technical details of hardware and software should not be given.

3.6. Doses

Doses of drugs should be expressed in mass terms, e.g. milligrams (mg) or grams (g), and also (in parentheses) in molar terms, e.g. mmol, mol, where this appears to be relevant. Molecular masses of many drugs may be found in *The Merck Index*. 11th ed. Rahway, NJ, U.S.A.: Merck and Co. Inc., 1989.

3.7. Enzymes

Nomenclature should follow that given in *Enzyme Nomenclature* (London and New York: Academic Press, 1984) and its supplements (*Eur. J. Biochem.* 1986; **157**, 1–26, and 1989; **179**, 489–533). The Enzyme Commission (EC) number should be quoted at the first mention. Where an enzyme has a commonly used informal name, this may be employed after the first formal identification. A unit of enzyme activity can be expressed as that amount of material which will catalyse transformation of 1 μ mol of the substrate/s under defined conditions, including temperature and pH. This gives the unit of the amount of enzyme named the katal (symbol kat). Alternatively, or when the natural substrate has not been

fully defined, activity should be expressed in terms of units of activity relative to that of a recognized reference preparation, assayed under identical conditions. Activities of enzymes should normally be expressed as units/ml or units/mg of protein.

3.8. Evaluation of measurement procedures

When a new measuring procedure has been used, or when an established procedure has been applied in a novel fashion, an estimate of the precision of the procedure should be given. This should, as far as possible, indicate what sources of variation have been included in this estimate, e.g. variation of immediate replication, variation within different times of day, or from day to day etc.

If the precision of measurement varies in proportion to the magnitude of the values obtained, it can best be expressed as the coefficient of variation; otherwise it should be expressed by an estimate of the (constant) standard error of a single observation, or by estimates of several points within the range of observed values.

When recovery experiments are described the approximate ratio of the amount added to the amount already present and the stage of the procedure at which the addition was made should be stated.

3.9. Figures and Tables

Their number should be kept to a minimum. Their appropriate position in the paper should be indicated in the margin of the text. References to Figures and Tables should be in Arabic numerals, e.g. Fig. 3, and they should be numbered in order of appearance. In general, the same data should not be presented in both a Figure and a Table.

Figures, with captions attached, should be supplied as original drawings or photographs together with photocopies. All Figures should have their number and the authors' names written in pencil on the back; the top of the Figure should be indicated with a pencilled arrow. Acceptable symbols for experimental points are \bullet , \blacktriangle , \blacksquare , \circ , \triangle , \square . The symbols \times or $+$ should be avoided. The same symbols must not be used for two curves where the points might be confused. For scatter diagrams, solid symbols are preferred. When a particular variable appears in more than one Figure, the same symbol should be used for it throughout, if possible.

Curves should not be drawn beyond the experimental points, nor should axes extend appreciably beyond the data. Only essential information that cannot readily be included in the legend should be written within the Figure.

Figures for half-tone reproduction should be submitted as glossy prints. **Four copies (not photocopies) of each print should be provided.**

Tables should be typed separately from the text. They should have an underlined title followed by any legend.

Captions for the Figures, and titles and legends for the Tables, should make them **readily understandable** without reference to the text. Adequate statistical information, including that on regression lines, should be included in Figure captions where appropriate.

3.10. Footnotes

These should be avoided as far as possible but where they are used in Tables they should be identified by the symbols * † ‡ § || ¶, in that order.

3.11. 'Homology'

The term 'homologous' has a precise meaning in biology of 'having a common evolutionary origin', but it has recently often been used in work on protein and nucleic acid sequences to mean simply 'similar'. A group of experts has urged that the interests of clarity are best served by restricting use to the more precise definition [Reeck, G. R. *et al.* (1987) *Cell* **40**, 667; Lewin, R. (1987) *Science* **237**, 1570]. *Clinical Science* agrees with these arguments and aims to preserve the distinction between 'homologous' and 'similar' in its pages.

3.12. Isotope measurements

The information given should include (a) conditions of radioactivity counting, e.g. infinitely thick, infinitely thin; (b) the nature of the phosphor used in liquid-scintillation counting; (c) details of corrections made to the observed count rate, e.g. for 'quenching' or 'cross-over'; (d) standard deviation of the results or a statement of the minimum total counts above background collected and the background value.

In general the specific radioactivity of the starting materials should be given, preferably in terms of radioactivity per unit weight or, for stable isotopes, as atoms % excess.

Pending the general introduction of SI units radioactivity should continue to be expressed in terms of the curie (Ci) followed by the corresponding figure in terms of the becquerel (Bq: disintegrations/s), in parentheses, and suitably rounded.

3.13. Radionuclide applications in man

If new or modified radionuclide applications in man are described, an estimate of the maximal possible radiation dose to the body and critical organs should be given.

For the time being this can continue to be expressed in rems, but with the corresponding figure in sieverts (Sv) given in parentheses after it.

3.14. Methods

In describing certain techniques, namely centrifugation (when the conditions are critical), chromatography and electrophoresis, authors should follow the recommendations published by the Biochemical Society (currently, *Biochem. J.* 1992; **281**, 1-19).

3.15. Nomenclature of disease

This should follow the International Classification of Disease (9th revision. Geneva: World Health Organization, 1979) as far as possible.

3.16. Powers in Tables and Figures

Care is needed where powers are used in Table headings and in Figures to avoid numbers with an incon-

venient number of digits. For example: (i) an entry '2' under the heading $10^3 k$ means that the value of k is 0.002; an entry '2' under the heading $10^{-3} k$ means that the value of k is 2000. (ii) A concentration 0.00015 mol/l may be expressed as 0.15 under the heading 'concn. (mmol/l)' or as 150 under the heading 'concn. ($\mu\text{mol/l}$)' or as 15 under the heading ' $10^5 \times \text{concn. (mol/l)}$ ', but not as 15 under the heading 'concn. ($\text{mol/l} \times 10^{-5}$)'.

3.17. References

The 'Vancouver' system is used: references in the text are numbered consecutively in the order in which they are first mentioned, the numerals being given in brackets, e.g. [22]. References cited in Figure legends or Tables only should be numbered in a sequence determined by the position of the first mention in the text of the Figure or Table. References should be listed in numerical order and the names of all authors of a paper should be given (except where there are seven or more when only the first three should be listed and *et al.* added), with the full title of the paper and the source details in full including the first and last page numbers, e.g.

2. Knox, A.J., Britton, J.R. & Tattersfield, A.E. Effect of vasopressin on bronchial reactivity to histamine. *Clin. Sci.* 1989; **77**, 467-71.

When the quotation is from a book, the following format should be used, giving the relevant pages or chapter number:

20. Armitage, P. *Statistical methods in medical research.* Oxford: Blackwell Scientific Publications, 1983.
21. Ghatei, M.A. & Bloom, S.R. Enteroglucagon in man. In: Bloom, S.R. & Polak, J.M., eds. *Gut hormones.* Edinburgh: Churchill Livingstone, 1981: 332-8.

References to 'personal communications' and 'unpublished work' should appear in the text only and not in the list of references. The name and initials of the source of information should be given. When the reference is to material that has been accepted for publication but has not yet been published, this should be indicated in the list of references by 'In press' together with the name of the relevant journal and, if possible, the expected date of publication. If such a citation is of major relevance to the manuscript submitted for publication authors are advised that the editorial process might be expedited by the inclusion of a copy of such work. In the case of quotations from personal communications the authors should state in the covering letter that permission for quotation has been obtained.

3.18. Solutions

Concentration of solutions should be described where possible in molar terms (mol/l and subunits thereof), stating the molecular particle weight if necessary. Values should not be expressed in terms of normality or equivalents. Mass concentration should be expressed as g/l or subunits thereof, for example mg/l or $\mu\text{g/l}$. For solutions of salts, molar concentration is always preferred to avoid

ambiguity as to whether anhydrous or hydrated compounds are used. Concentrations of aqueous solutions should be given as mol/l or mol/kg (g/l or g/kg if not expressed in molar terms) rather than % (w/v) or % (w/w). It should always be made clear whether concentrations of compounds in a reaction mixture are final concentrations or the concentrations in solutions added.

3.19. Spectrophotometric data

- The general name for the quantity $\log(I_0/I)$ is attenuation, and it reduces to absorbance when there is negligible scattering or reflection. The more general term 'attenuance' should be used when scattering is considerable, e.g. when the quantity is measured to estimate the cell density of a culture. Otherwise the term absorbance should be used; neither should be called extinction or optical density. Symbols used are: *A*, absorbance; *D*, attenuation; *a*, specific absorption coefficient (litre $\text{g}^{-1} \text{cm}^{-1}$) (alternatively use $A_{1\text{cm}}^{1\%}$); ϵ , molar absorption coefficient (the absorbance of a molar solution in a 1 cm light-path) (litre $\text{mol}^{-1} \text{cm}^{-1}$, *not* $\text{cm}^2 \text{mol}^{-1}$).

3.20. Spelling

Clinical Science uses as standards for spelling the Concise or Shorter Oxford Dictionary of Current English (Oxford: Clarendon Press) and Butterworth's Medical Dictionary (London: Butterworths).

3.21. Statistics

Papers are frequently returned for revision (and their publication consequently delayed) because the authors use inappropriate statistical methods. Two common errors are the use of means, standard deviations and standard errors in the description and interpretation of grossly non-normally distributed data and the application of *t*-tests for the significance of difference between means in similar circumstances, or when the variances of the two groups are non-homogeneous. In some circumstances it may be more appropriate to provide a 'scattergram' than a statistical summary. Authors are recommended to consult the statistical guidelines presented by Altman *et al.* in 'Statistical guidelines for contributors to medical journals' *Br. Med. J.* 1983; **286**, 1489–93.

The type of statistical test used should be stated in the Methods section. A reference should be given for the less commonly encountered statistical tests. The format for expressing mean values and standard deviations or standard errors of the mean is, for example: mean cardiac output 10.4 l/min (sd 1.2; $n = 11$). Degrees of freedom should be indicated where appropriate. Levels of significance are expressed in the form $P < 0.01$.

3.22. Trade names

The name and address of the supplier of special apparatus and of biochemicals should be given. In the case of drugs, approved names should always be given with trade names and manufacturers in parentheses.

4. UNITS: THE SI SYSTEM

The recommended Système International (SI) units (see Quantities, units and symbols in physical chemistry. Oxford: Blackwell Scientific Publications Ltd, 1988) are used by *Clinical Science*. **All papers submitted should use these units** except for blood pressure values, which should be expressed in mmHg, and gas partial pressures, where values at the author's discretion may be given in mmHg (with kPa in parentheses) or as kPa (with mmHg in parentheses). Airways pressure should be expressed in kPa. Where molecular mass is known, the amount of a chemical or drug should be expressed in mol or in an appropriate subunit, e.g. mmol. Energy should be expressed in joules (J).

The basic SI units and their symbols are as follows:

Physical quantity	Name	Symbol
length	metre	m
mass	kilogram	kg
time	second	s
electric current	ampere	A
thermodynamic temperature	kelvin	K
luminous intensity	candela	cd
amounts of substance	mole	mol

The following are examples of derived SI units:

Physical quantity	Name	Symbol	Definition
energy	joule	J	$\text{kg m}^2 \text{s}^{-2}$
force	newton	N	$\text{kg m s}^{-2} = \text{J m}^{-1}$
power	watt	W	$\text{kg m}^2 \text{s}^{-3} = \text{J s}^{-1}$
pressure	pascal	Pa	$\text{kg m}^{-1} \text{s}^{-2} = \text{N m}^{-2}$
electric charge	coulomb	C	A s
electric potential difference	volt	V	$\text{kg m}^2 \text{s}^{-2} \text{A}^{-1} = \text{J A}^{-1} \text{s}^{-1}$
electric resistance	ohm	Ω	$\text{kg m}^2 \text{s}^{-3} \text{A}^{-2} = \text{V A}^{-1}$
electric conductance	siemens	S	$\text{kg}^{-1} \text{m}^{-2} \text{s}^3 \text{A}^2 = \Omega^{-1}$
electric capacitance	farad	F	$\text{A}^2 \text{s}^3 \text{kg}^{-1} \text{m}^{-2} = \text{A s V}^{-1}$
frequency	hertz	Hz	s^{-1}
volume	litre	l	10^{-3}m^3

The word 'litre' has been accepted as a special name for cubic decimetre (1 litre = 1 dm^3).

Both the basic and derived SI units, including the symbols of derived units that have special names, may be preceded by prefixes to indicate multiples and sub-multiples. The prefixes should be as follows:

Multiple	Prefix	Symbol	Multiple	Prefix	Symbol
10^6	mega	M	10^{-3}	milli	m
10^3	kilo	k	10^{-6}	micro	μ
10^2	hecto	h*	10^{-9}	nano	n
10	deka	da	10^{-12}	pico	p
10^{-1}	deci	d*	10^{-15}	femto	f
10^{-2}	centi	c*			

*To be avoided where possible (except for cm).

Compound prefixes should not be used, e.g. 10^{-9} m should be represented by 1 nm, not 1 m μm .

Notes:

- (i) Full stops are not used after symbols.
 (ii) Minutes (min), hours (h), days and years will continue to be used in addition to the SI unit of time [the second (s)].
 (iii) The solidus may be used in a unit as long as it does not have to be employed more than once, e.g. mmol/l is acceptable, but ml/min/kg is not, and should be replaced by $\text{ml min}^{-1} \text{kg}^{-1}$.

5. ABBREVIATIONS, CONVENTIONS, DEFINITIONS, SYMBOLS AND SPECIAL COMMENTS

Standard symbols and abbreviations that have been accepted by international bodies can be used without definition and are indicated by an asterisk; this list also shows selected abbreviations in the form of groups of capital letters (e.g. ALA, ECF, MCHC) which when used must be defined in the text as indicated on p. iii. The standard abbreviations for amino acids are only for use in Figures and Tables or for peptide sequences.

absorbance	A	bovine serum albumin	BSA*
acceleration due to gravity	g	British Pharmacopoeia calculated	write in full and give edition calc. (in Tables only)
adenosine 3',5'-cyclic monophosphate	cyclic AMP*	'Calorie' (= 1000 cal)	<i>not used</i> ; recalculate as kilojoules (1 'Calorie' = 4.184 kJ)
adenosine 5'-phosphate	AMP*	carbon dioxide output (in respiratory physiology)	\dot{V}_{CO_2} ; express in ml STP/min
adenosine 5'-diphosphate	ADP*	cardiac frequency	f_c ; in beats/min
adenosine triphosphatase	ATPase*	cardiac output	express in l/min
adenosine 5'-triphosphate	ATP*	centimetre	cm
adrenoceptor (<i>see also</i> blocking agents)		clearance of x	C_x
adrenocorticotrophic hormone	ACTH	coenzyme A and its acyl derivatives	CoA* and acyl-CoA*
alanine	Ala	compare	cf.
alternating current	a.c.*	complement fractions	C1-C9*
alveolar minute ventilation	\dot{V}_A	compliance (respiratory physiology)	C; express in l kPa ⁻¹
alveolar to arterial oxygen partial pressure difference	($P_{\text{AO}_2} - P_{\text{aO}_2}$)	concentrated concentration	conc.
aminolaevulinic acid	ALA	conductance (respiratory physiology)	concn.; may be denoted []; e.g. plasma [HCO_3^-]
ampere	A	correlation coefficient	r
angiotensin	ANG; reference amino acid abbreviations are used as prefix within brackets: e.g. [Sar ¹ , Val ⁵ , Ala ⁸]ANG	counts/min, counts/s	c.p.m.*, c.p.s.*
Ångstrom (Å)	<i>not used</i> ; express in nm (1 Ångstrom = 10^{-1} nm)	cubic centimetres	<i>use</i> ml
antidiuretic hormone	ADH (when referring to the physiological secretion)	curie	Ci (1 Ci = 3.7×10^{10} d.p.s.)
arginine	Arg	cycle/s	Hz
arteriovenous	a-v: <i>permitted</i> in Figures and Tables	cysteine	Cys
asparagine	Asn	dates	e.g. 11 August 1970
aspartic acid	Asp	dead-space minute ventilation	\dot{V}_D
atmosphere (unit of pressure)	<i>not used</i> ; express in kPa (1 atmosphere = 101.325 kPa)	dead-space volume	V_D
▶ attenuation	D	degrees, Celsius or centigrade	°C
▶ base pair	bp	deoxy (prefix)	<i>not desoxy</i>
becquerel	Bq (1 d.p.s.)	deoxycorticosterone	DOC
blocking agents	e.g. β -adrenoceptor antagonists preferred	deoxycorticosterone acetate	DOCA
blood pressure	express in mmHg	deoxyribonucleic acid	DNA*
blood urea nitrogen	<i>not used</i> ; recalculate as urea, express in mmol/l	dialysate	diffusate preferred; 'dialysate' should be clearly defined
blood volume	BV	diethylaminoethylcellulose	DEAE-cellulose*
body temperature and pressure, BTPS* saturated		differential of x with respect to time	\dot{x} (= dx/dt)
		1,25-dihydroxycholecalciferol	1,25-(OH) ₂ D ₃
		dilute	dil.
		2,3-diphosphoglycerate	2,3-DPG
		direct current	d.c.*
		disintegrations/min	d.p.in.*
		disintegrations/s	d.p.s.*
		dissociation constant	
		acidic	K_a
		apparent	e.g. K'_a
		basic	K_b
		minus log of	pK
		doses	avoid Latin designations such as b.d. and t.i.d.
		dyne	dyn; used for vascular resistance
		elastance	E; express in Pa m ⁻³
		electrocardiogram	ECG*
		electroencephalogram	EEG*
		electromotive force	e.m.f.*
		electron spin resonance	e.s.r.*
		electronvolt	eV (for radiation energies)
		enzyme-linked immunosorbent assay	e.l.i.s.a.*
		equation	eqn.
		equivalents (amount of a chemical)	<i>not used</i> ; recalculate in molar terms
		erythrocyte count	express as 10^{12} cells/l
		erythrocyte sedimentation rate	ESR
		ethanol, ethanolic	not ethyl alcohol or alcoholic
		ethylenediaminetetra-acetate	EDTA*
		'ethyleneglycolbis(aminoethyl-ether)tetra-acetate'	EGTA*

packed cell volume	PCV	solvent systems	e.g. butanol/acetic acid/water (4:1:1, by vol.), butanol/acetic acid (4:1, v/v)
page, pages	p., pp.	sodium dodecyl sulphate	SDS*
<i>para-</i>	<i>p-</i>	species	sp., plural spp.
<i>para</i> -aminohippurate	PAH	specific activity	sp. act. Confusion must be avoided between e.g. specific radioactivity and the specific activity of an enzyme
partial pressure	<i>P</i> ; express in either kPa or mmHg (see p. vi)	specific conductance of airways	sGaw; express in s ⁻¹ kPa ⁻¹
e.g. alveolar, of O ₂	<i>P</i> _{AO₂}	standard deviation	SD*
arterial, of CO ₂	<i>P</i> _{aCO₂}	standard error of the mean	SEM*
capillary, of O ₂	<i>P</i> _{capO₂}	standard temperature and pressure	STP*
end-tidal, of CO ₂	<i>P</i> _{ETCO₂}	steroid nomenclature	see Eur. J. Biochem. 1989; 186 , 429–58
mixed venous, of CO ₂	<i>P</i> _{v̄CO₂}	sulphydryl	use thiol or SH
pascal	Pa	sum	Σ
per	/	Svedberg unit	S
per cent	%	temperature (absolute)	<i>T</i>
petroleum ether	<i>not used</i> ; use light petroleum and give boiling range	(empirical)	<i>t</i>
phenylalanine	Phe	temperature, thermodynamic	K
plasma renin activity	express as pmol of angiotensin I h ⁻¹ ml ⁻¹	thin-layer chromatography	t.l.c.*
plasma volume	PV	threonine	Thr
poise	1 poise = 10 ⁻¹ N s m ⁻²	thyrotrophic hormone	TRH
polyacrylamide-gel electrophoresis	PAGE*	thyrotrophin-releasing hormone	TRH
potential difference	p.d.	tidal volume	<i>V</i> _T
power output	W (1 kpm/min = 0.1635 W)	time (symbol)	<i>t</i>
precipitate	ppt.	time of day	e.g. 18.15 hours
pressure	<i>P</i> ; express in kPa (except for blood pressures and gas partial pressures: see p. vi); 1 kPa = 7.5 mmHg	total lung capacity	TLC
probability of an event being due to chance alone	<i>P</i>	torr	not used; use kPa (1 torr = 0.133 kPa)
proline	Pro	tryptophan	Trp
pulmonary capillary blood flow	\dot{Q}_c	tubular maximal reabsorptive capacity for x	<i>T</i> _{m, x}
pyrophosphate (inorganic)	PP _i *	tyrosine	Tyr
rad (radiation dose; 10 ⁻⁵ J absorbed/g of material)	not abbreviated (100 rads = 1 Gy)	ultraviolet	u.v.*
radioimmunoassay	r.i.a.*	urinary concentration of x	<i>U</i> _x
red blood cell	use erythrocyte; express counts as 10 ¹² cells/l	valency	e.g. Fe ²⁺ , <i>not</i> Fe ⁺⁺
relative band speed (partition chromatography)	<i>R</i> _F	valine	Val
rem	100 ergs/s × quality factor	variance ratio	<i>F</i>
renin	see plasma renin activity	vascular resistance	express in kPa l ⁻¹ s (with value in dyn s cm ⁻⁵ in parentheses); primary values of differential vascular pressure (mmHg) and flow (l/min) should always also be given in Tables or text as appropriate
residual volume	RV	velocity	<i>v</i> ; express as m s ⁻¹
resistance (rheological)	<i>R</i> ; express in kPa l ⁻¹ s	venous admixture	\dot{Q}_{va}
respiratory exchange ratio (pulmonary)	<i>R</i>	viscosity, dynamic	η
respiratory quotient (metabolic)	RQ	viscosity, kinematic	<i>v</i>
revolutions	rev.	vital capacity	VC
rev./min	<i>not</i> r.p.m.; use <i>g</i> if possible (see p. viii)	volt	V
ribonucleic acid	RNA*	volume of blood (in cardio-respiratory physiology)	\dot{Q} ; use \dot{Q} for blood flow rate
röntgen	R	watt	W
saline	define at first mention [e.g. NaCl solution (154 mmol/l)]	wavelength	λ
saturation	<i>S</i> , e.g. S _{aO₂} for arterial oxygen saturation (see partial pressure for other analogous abbreviations)	weight	wt.
second (time)	s	white blood cell	use leucocyte; express counts as 10 ⁹ cells/l
serine	Ser		
sievert	Sv (1 J/kg × quality factor)		